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Introduction
Juvenile Dermatomyositis (JDM) is a rare serious disease
(affecting 2-3 million children/year) presenting with rash
and proximal muscle weakness. Serious complications
can include calcinosis, GI ulceration, interstitial lung
disease (ILD) and even death. It is becoming clear that
JDM is a heterogeneous condition. Dividing JDM into
sub-phenotypes would allow better prediction of disease
severity and more targeted treatments. We have identi-
fied novel auto-antibodies in subtypes of JDM that may
correlate with specific phenotypes.
Objectives
To define clinical & pathological phenotypes of
patients with JDM who have antibodies to Melanoma
Differentiation-Associated protein 5 (MDA-5).
Methods
Patients
Patients were included from the Juvenile Dermatomyositis
Cohort and Biomarker Study, a multi-centre study includ-
ing 13 centres from across the UK. The study collects
longitudinal clinical and serological data from patients
with idiopathic inflammatory myopathies (IIM) of which
85% are diagnosed with JDM or JDM overlap features
(currently n=446 patients). Clinical data collected included
presence of clinical features, treatment, physicians global
assessment and muscle strength assessments including the
Childhood Muscle Assessment Score (CMAS).
Autoantibodies
Plasma or serum, available for 285 patients, were screened
for the presence of autoantibodies by immunoprecipitation
and confirmed by ELISA using recombinant MDA-5
protein.
Muscle biopsies
Muscle biopsies were stained and scored using the JDM
Muscle biopsy score tool as described (1,2) .The validated
muscle biopsy score tool measures severity of muscle
pathology across 4 domains and with a separate visual
assessment score (0-10).
Results
Autoantibody screening identified the presence of MDA-5
antibodies in 7.4% of patients (21/285 cases). MDA-5
positive patients had significantly increased incidence of
ulceration (p=0.03), arthritis (p<0.01) and lung disease, yet
had less severe muscle involvement, measured by CMAS
score (p=0.03), than MDA-5 negative patients. In addition,
median muscle biopsy scores for the MDA-5+ve patients
were significantly lower than the MDA-5-ve patients
(p<0.005) suggesting a less severe muscle pathology.
Conclusion
JDM is a heterogeneous condition with sub-phenotypes
defined by autoantibody status, clinical features and
muscle pathology. Identification and classification of
sub-phenotypes could be used to predict disease course
and severity. In the future, JDM specific autoantibodies
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